Cytomegalovirus Post Transplant - New Drug
The FDA has approved the use of Maribavir (Livtencity) to treat episodes of post transplant CMV for recipients 12 and up. This is an important advance for those who do not respond to typical anti-virals.
"Transplant recipients are at a much greater risk for complications and death when faced with a cytomegalovirus infection," John Farley, MD, director of FDA's Office of Infectious Diseases, said in a statement. "Today's approval helps meet a significant unmet medical need by providing a treatment option for this patient population."
Interestingly, recipients interviewed in my research project identified CMV overwhelmingly as the one issue they wished doctors would have discussed more thoroughly. Even recipients who accepted Hep C + hearts considered CMV to produce more severe health problems.
Here is the link to the article I found.